GILD Acquires Tubulis
Gilead Sciences expands oncology portfolio with $3.15B acquisition of Tubulis, bolstering its cancer treatment offerings
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.